Processing your request


please wait...

Case Page

 

Case Status:    ONGOING    
On or around 04/01/2020 (Date of last review)

Filing Date: March 25, 2020

According to the Complaint, Anaptysbio, Inc.is a clinical stage biotechnology company focused on the discovery and development of drugs for the treatment of inflammation and immuno-oncology conditions with unmet medical needs. During the Class Period, the Company's lead drug asset was etokimab (formerly ANB020), a drug intended for the treatment of various inflammatory diseases.

The Complaint alleges that, throughout the Class Period, Defendants made false and misleading statements regarding the purported efficacy of etokimab, touting data from the Company's Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and describing the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis based on AnaptysBio's Phase 2a trial data for that indication. Specifically, the Complaint alleges Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ANAB
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. California
DOCKET #: 20-CV-00565
JUDGE: Hon. Thomas J. Whelan
DATE FILED: 03/25/2020
CLASS PERIOD START: 10/10/2017
CLASS PERIOD END: 11/07/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Bernstein Litowitz Berger & Grossman LLP (LA)
  2. Klausner Kaufman Jensen & Levinson
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available